Leadership

 

121102_JF_RSZD.JPG

Jackie Fairley, B.Sc, B.VSc (Hons), MBA, GAICD, FTSE 
Chief Executive Officer

Dr Jackie Fairley has more than 30 years of operational experience in the pharmaceutical and biotechnology industries working in senior management roles with companies including CSL and Faulding/Hospira (now part of Pfizer). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006. She holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from the University of Melbourne and was a practicing veterinary surgeon prior to joining CSL. Whilst at CSL she obtained an MBA from the Melbourne Business School where she was the recipient of the prestigious Clemenger Medal. Jackie is a non-executive director of the listed investment company Mirrabooka Investments Limited, is a member of the Invest Victoria Advisory Board (IVAB) and Carnegie Venture Capital’s investment Committee.  She has previously served on the Melbourne Business School Board, the Australian Federal Government’s Commonwealth Science Council and Pharmaceutical Industry Working Group and the Australian Federal Ministerial Biotechnology Advisory Council.

131209_TE_v2.jpg

Tony Eglezos, B.Sc (Hons), PhD, MBA
Vice President, Business Development 

Dr Eglezos has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australasia. Most recently he was Director Commercial Operations, Pharmaceuticals, and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL. During his 7 years in business development with CSL, Tony’s responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group. Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney.

121102_JP_RSZD.JPG

Jeremy Paull, B.Sc (Hons), PhD
Vice President, Development and Regulatory Affairs

Dr Jeremy Paull has more than 20 years’ experience in pharmaceutical and medtech product development, regulatory affairs, and commercialisation.  Jeremy has managed all aspects of multiple development and commercialisation projects for products in areas including HIV/STIs, infectious diseases, women’s health, dermatology, and oncology, and has achieved market approval and commercialisation of medical device and combination products in global markets. Jeremy has also advanced pharmaceutical products through late stage, global phase 3 clinical trials, and led engagement with global regulatory agencies (FDA, EMA, TGA, MHRA, PMDA). Jeremy leads a team of senior technical managers and was Principal Investigator for two concurrent US NIH-funded, multi-year, multi-million dollar research and product commercialisation programs involving collaborations with world-renowned, local and international academic institutions and commercial partners. He is a current member of AusBiotech’s AusMedtech Regulatory Affairs Expert Panel and past member of the AusMedtech Victoria Committee. Jeremy has been a member of the executive leadership team of Starpharma since 2003 and has completed executive leadership training at Kellogg School of Management at Northwestern University, Melbourne Business School, and Australian Graduate School of Management at UNSW. He joined Starpharma in 2001 from medtech company, Norwood Abbey, and has a PhD in pharmacology from Monash University.

 

121102_NB_RSZD.JPG

Nigel Baade, B.Com, CPA, Grad Dip Arts (Development)
Chief Financial Officer 

Mr Nigel Baade has held the position of Chief Financial Officer since January 2009. Previously, Mr Baade also held the position of Company Secretary from 2013 until the end of January 2023. Mr Baade is a Certified Practising Accountant (CPA) with extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Starpharma as Financial Controller in 2006, he has held positions at Hagemeyer, Cerylid Biosciences, Faulding (now Pfizer) and UMT (Fonterra). Mr Baade holds qualifications from University of Tasmania and Monash University.  Mr Baade is a former director of BioMelbourne Network Inc and served as its Treasurer and Chairman of the Finance, Audit and Risk Committee. Mr Baade is a member of the Australian Institute of Company Directors.